Passa al contenuto
Merck
Tutte le immagini(2)

Documenti fondamentali

Visualizza tutta la documentazione

F9397

Sigma-Aldrich

Flutamide

Sinonimo/i:

2-Methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(2)

About This Item

Formula empirica (notazione di Hill):
C11H11F3N2O3
Numero CAS:
13311-84-7
Peso molecolare:
276.21
Numero CE:
236-341-9
Numero MDL:
MFCD00072009
Codice UNSPSC:
51111800
ID PubChem:
24278446
NACRES:
NA.77

Livello qualitativo

100

Ideatore

Schering Plough

Stringa SMILE

CC(C)C(=O)Nc1ccc(c(c1)C(F)(F)F)[N+]([O-])=O

InChI

1S/C11H11F3N2O3/c1-6(2)10(17)15-7-3-4-9(16(18)19)8(5-7)11(12,13)14/h3-6H,1-2H3,(H,15,17)
MKXKFYHWDHIYRV-UHFFFAOYSA-N

Informazioni sul gene

human ... AR(367)
mouse ... Ar(11835)
rat ... Ar(24208)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Applicazioni

Flutamide has been used to effect of testosterone on Glial cell-derived neurotrophic factor (Gdnf) mRNA production in vitro. It has also been used to study the effects of flutamide on anogenital distance and nipple retention.

Azioni biochim/fisiol

Flutamide is a non-steroidal anti-androgen drug. It consists of a nitroaromatic structure. Flutamide is a potent competitor of testosterone and dihydrotestosterone receptors. It is a potent hepatotoxin.

Caratteristiche e vantaggi

This compound was developed by Schering Plough. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Avvertenze

Warning

Indicazioni di pericolo

H302,H351,H361,H373,H411

Classi di pericolo

Acute Tox. 4 Oral - Aquatic Chronic 2 - Carc. 2 - Repr. 2 - STOT RE 2

Organi bersaglio

Liver

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Dispositivi di protezione individuale

Eyeshields, Gloves, type P3 (EN 143) respirator cartridges

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number
MKCP9859
MKCL6929
MKCK9955
MKCG9741
MKBW6122V

Non trovi la versione di tuo interesse?

Se hai bisogno di una versione specifica, puoi cercare il certificato tramite il numero di lotto.

Cerca un COA

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 7

1 of 7

Testosterone purum, ≥99.0% (HPLC)

Sigma-Aldrich

86500

Testosterone

Bicalutamide British Pharmacopoeia (BP) Reference Standard

BP1115

Bicalutamide

Finasteride ≥98% (HPLC), powder

Sigma-Aldrich

F1293

Finasteride

VPC-13566 ≥98% (HPLC)

Sigma-Aldrich

SML1886

VPC-13566

Fulvestrant >98% (HPLC)

Sigma-Aldrich

I4409

Fulvestrant

Abiraterone acetate ≥98% (HPLC)

Sigma-Aldrich

SML1527

Abiraterone acetate

Bicalutamide Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1678

Bicalutamide

Shuchen Gu et al.
Cellular signalling, 25(1), 66-73 (2013-01-15)
Actin cytoskeleton reorganization initiated by testosterone conjugates through activation of membrane androgen receptors (mAR) has recently been reported in colon tumor cells. This mAR-induced actin reorganization was recognized as a critical initial event, controlling apoptosis and inhibiting cell migration. The
N A Spry et al.
Prostate cancer and prostatic diseases, 16(1), 67-72 (2012-08-22)
To examine changes to whole body and regional lean mass (LM) and fat mass (FM) over 33 months of intermittent androgen suppression therapy (IAST). Phase II cohort study of 72 prostate cancer patients without metastatic bone disease. Patients received flutamide
Combined exposure to anti-androgens exacerbates disruption of sexual differentiation in the rat
Hass U, et al.
Environmental Health Perspectives, 115(Suppl 1), 122-128 (2007)
Flutamide-induced hepatotoxicity: ethical and scientific issues
Giorgetti R, et al.
European Review for Medical and Pharmacological Sciences, 21(1 Suppl), 69-77 (2017)
Palakkil Mavilavalappil Sandeep et al.
Metabolic syndrome and related disorders, 13(6), 248-254 (2015-04-29)
Polycystic ovary syndrome (PCOS) is a major hyperandrogenic disorder. Many drugs prescribed specifically to treat PCOS have side effects; however, previous studies suggest that natural therapeutics including botanicals may be less invasive and equally effective for the management of PCOS.
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.